Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19285954 | 0.91 | SHBG (0.36) | SHBGGRIA4RIPK1CYP3A4SMN1; SMN2 | |
| SCHEMBL14685562 | 0.82 | CYP2D6 (0.40) | SHBGCYP3A4SMN1; SMN2PDE2ATP53 | |
| SCHEMBL14149992 | 0.81 | PDE2A (0.35) | SHBGGRIA4PDE2ATP53TSHR | |
| SCHEMBL21933684 | 0.81 | PDE2A (0.37) | SHBGGRIA4RIPK1PDE2A | |
| SCHEMBL8352192 | 0.79 | SHBG (0.50) | SHBGCYP3A4SMN1; SMN2PDE2ATP53 | |
| SCHEMBL5918492 | 0.79 | RIPK1 (0.46) | GRIA4RIPK1 | |
| SCHEMBL25871900 | 0.77 | SHBG (0.61) | SHBGCYP3A4SMN1; SMN2PDE2ATP53 | |
| SCHEMBL23956932 | 0.75 | TAAR1 (0.39) | GRIA4RIPK1CYP3A4PDE2A | |
| SCHEMBL24533708 | 0.74 | GRIA4 (0.38) | SHBGGRIA4RIPK1PDE2A | |
| SCHEMBL23221272 | 0.73 | SHBG (0.45) | SHBGCYP3A4SMN1; SMN2TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149066-B2 | Thrombospondin 1-binding peptide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-10-19 | — | — | US | disclosed |
| US-20200131230-A1 | THROMBOSPONDIN 1-BINDING PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149066-B2 | Thrombospondin 1-binding peptide | SERPINC1, TEK, ARGLU1 | SHBG 1524/4885GRIA4 1608/4885RIPK1 1243/4885 |
| US-20200131230-A1 | THROMBOSPONDIN 1-BINDING PEPTIDE | SERPINC1, TEK, ARGLU1 | SHBG 1524/4885GRIA4 1608/4885RIPK1 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.